First clinical data for sutacimig in Factor VII deficiency (FVIID) shows multi-fold accumulation of endogenous FVII(a) with shortening of prothrombin time after a single subcutaneous dose in initial participants of the Phase 2b study Preclinical data show HMB-003 reduced severe menstrual bleeding in a cynomolgus monkey model of menstrual bleeding CAMBRIDGE, Mass. and COPENHAGEN, Denmark , Nov. 04, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq:COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced two presentations showcasing progress from multiple pipeline programs at the upcoming 68th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, Louisiana , and virtually from December 12–15, 2026. “We are excited to present the first clinical data for sutacimig in Factor VII deficiency at ASH,” said Benny Sørensen , MD, PhD, CEO of Hemab. “People living with this disease have no approved prophylactic option and face the constant risk of unpredictable, sometimes life-threatening bleeds. Seeing sustained accumulation of Factor VII and a meaningful shortening of prothrombin time after a single dose is an encouraging first step, and it strengthens our belief that sutacimig could bring the freedom of an infrequent, subcutaneous prophylactic treatment to these patients. We are equally energized by the preclinical data for HMB-003, which continue to reinforce our enthusiasm for its potential. Week-long antifibrinolytic activity that returns to baseline between cycles, together with fewer severe bleeding days in a primate model, is exactly the profile we hoped to see as we work toward a non-hormonal, long-acting option for the millions of women living with heavy menstrual bleeding.” The Company will present the first pharmacokinetic (PK) and pharmacodynamic (PD) results from its ongoing Phase 2b study of sutacimig in congenital FVIID, in which a single subcutaneous dose produced sustained accumulation of endogenous FVII(a) and shortened prothrombin time. For HMB-003, preclinical data will show potent, selective plasmin inhibition with a reduction in severe menstrual bleeding days in a cynomolgus monkey model of menstrual bleeding. HMB-003 is now in a Phase 1 clinical trial, with initial clinical data expected in mid-2027. Presentation Highlights and Details – The abstracts are now available through the ASH conference website Sutacimig The poster reports the first clinical evidence for sutacimig in FVIID, from the single ascending dose cohort of the Phase 2b study, HMB-001-201 (NCT07347249), that is being conducted at a single site in the UK . As of July 24, 2026 , two participants with severe congenital FVIID had received a single subcutaneous dose of sutacimig. Adverse events were low grade and assessed as not related to treatment. Both participants had a baseline prothrombin time of ≥180 seconds, which shortened by more than 50% following dosing. In the participant with PK/PD data available to date, sutacimig produced sustained accumulation (~5x) of endogenous total FVII(a), with exposure maintained through Day 22, supporting the potential feasibility of an infrequent dosing regimen pending additional data. Updated data for all dosed participants will be presented at the meeting. Abstract Number : abs26-10755 Format : Poster Title : Sutacimig, a subcutaneous FVIIa-targeting bispecific antibody, in congenital factor VII deficiency: First pharmacokinetic and pharmacodynamic results from a Phase 2 study Date and Time : December 14, 2026 , 6:00 PM – 8:00 PM CT Room : MCCNO - Hall F HMB-003 In human plasma and whole blood, HMB-003 inhibited fibrinolysis in a concentration-dependent manner, with no observed effect on thrombin generation or platelet aggregation in human plasma. In minipigs, a single subcutaneous dose reached peak plasma levels within hours and had a terminal half-life of 6 to 7 days, with complete ex vivo inhibition of fibrinolysis for up to 7 days followed by a full return to baseline. In a cynomolgus monkey model of menstrual bleeding, HMB-003 reduced the proportion of severe bleeding days and shifted bleeding toward lower intensity compared with the baseline observation phase. These data support HMB-003 as a potential non-hormonal therapy for heavy menstrual bleeding with antifibrinolytic activity intended to cover the heaviest bleeding days. The Phase 1 trial of HMB-003 (NCT07798505) in healthy volunteers is ongoing, with initial clinical data expected in mid-2027. Abstract Number : abs26-5938 Format : Poster Title : HMB-003, a novel selective plasmin inhibitor engineered for week-long antifibrinolytic activity, reduced severe menstrual bleeding in cynomolgus monkey Date and Time : December 13, 2026 , 6:00 PM – 8:00 PM CT Room : MCCNO - Hall F About Factor VII Deficiency Factor VII deficiency (FVIID) is a congenital severe bleeding disorder charact